Major CVD event risk cut by 20% in adults without diabetes, with overweight or obesity
November 11, 2023
November 11, 2023
DALLAS, Texas, Nov. 11 [Category: Health Care] -- The American Heart Association issued the following news release:
Research Highlights:
In a large, international clinical trial, people with obesity or overweight but not diabetes taking semaglutide for more than 3 years had a 20% lower risk of heart attack, stroke or death due to cardiovascular disease and lost an average of 9.4% of their body weight. Semaglutide is a GLP-1 medication primarily prescribed for people wit . . .
Research Highlights:
In a large, international clinical trial, people with obesity or overweight but not diabetes taking semaglutide for more than 3 years had a 20% lower risk of heart attack, stroke or death due to cardiovascular disease and lost an average of 9.4% of their body weight. Semaglutide is a GLP-1 medication primarily prescribed for people wit . . .